Precursor of imidazole-based bioactive substance and production method for imidazole-based bioactive substance

Imidazole-based physiologically active substance precursors with a 2H-imidazole-2-amine skeleton address solubility and activation issues by responding to external stimuli, allowing controlled and targeted activation for improved therapeutic applications.

JP2024159542APending Publication Date: 2024-11-08HOKKAIDO UNIVERSITY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024061542
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-04-26
Filing Date
2024-04-05
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

Existing imidazole-based physiologically active substances face issues with low solubility in water and non-specific activation, leading to unwanted side effects on normal cells and inefficient control over physiological activity.

Method used

Development of imidazole-based physiologically active substance precursors with a 2H-imidazole-2-amine skeleton that respond to external stimuli or environmental conditions, such as light or reducing environments, to selectively generate active substances.

Benefits of technology

Enables precise control over the activation of imidazole-based substances at desired locations and timings, reducing side effects on normal cells and enhancing therapeutic efficacy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024159542000015
    Figure 2024159542000015
  • Figure 2024159542000016
    Figure 2024159542000016
  • Figure 2024159542000017
    Figure 2024159542000017
Patent Text Reader

Abstract

To provide a precursor of an imidazole-based bioactive substance that produces the imidazole-based bioactive substance in response to an external stimulation or environment, and a production method for the imidazole-based bioactive substance.SOLUTION: A precursor of an imidazole-based bioactive substance has a 2H-imidazole-2-amine skeleton in its molecular structure and produces the imidazole-based bioactive substance in response to an external stimulation or environment.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to precursors of imidazole bioactive substances and methods for producing imidazole bioactive substances. [Background technology]

[0002] Transforming growth factor-β (TGF-β) was initially identified as a growth factor that promotes the transformation of fibroblasts. However, in recent years, it has been revealed that TGF-β also contributes to the inhibition of proliferation, cell differentiation, and induction of apoptosis in many cell types. For example, it has been reported that TGF-β promotes the proliferation of osteoblasts and the synthesis and proliferation of connective tissues such as collagen, while suppressing the proliferation of epithelial cells and osteoclasts. Therefore, like other growth factors, TGF-β is also involved in cell differentiation, migration, and adhesion, and is thought to play an important role in a wide range of areas such as individual development, tissue reconstruction, wound healing, inflammation, immunity, and cancer invasion and metastasis. Serine / threonine kinases of type I receptors (such as ALK5) activated by binding with TGF-β phosphorylate Smad2 / 3 proteins, thereby transmitting signals into cells. SB-431542 is a drug candidate developed as an inhibitor of such kinase receptors, ALK5, ALK4, and ALK7 (Non-Patent Document 1). Although SB-431542 has not yet been applied clinically, various physiological activities expected as a drug have been reported, such as suppressing the growth of glioma, a malignant brain tumor (Non-Patent Document 2), reducing the number of fibrocytes in damaged muscles in rotator cuff tears (Non-Patent Document 3), and reducing the amount of infectious virus particles produced by SARS-CoV-2 (Non-Patent Document 4). In addition, since SB-431542 inhibits various phenomena induced by TGF-β, it is actively used as an important molecular tool in molecular biology to study phenomena involving TGF-β (Non-Patent Document 5). However, SB-431542 has the problem that it is essentially low in solubility in water, which is important when applied to living organisms. In addition, in the application as a drug, there is a demand to reduce side effects on normal cells. Furthermore, as a molecular tool in molecular biology research, there is a demand for a molecular tool that can be used under more selective conditions so that the inhibitory effect appears only at the desired timing and place.

[0003] On the other hand, brain degenerative diseases such as stroke, Parkinson's disease, and Alzheimer's disease are seen all over the world, but they arise from the loss of nerve cells. In recent years, the development of small molecules that differentiate stem cells into nerve cells has provided the possibility of a new therapeutic approach to the treatment of these diseases. However, this approach requires a sufficient stem cell source, precise control of differentiation, suppression of the host's rejection of allogeneic cells, and prevention of tumor formation by undifferentiated cells. More interesting small molecules are those that have the ability to induce neurogenesis in easily available cells and tissues such as myoblasts and muscle tissue. Neurodazine, an imidazole derivative, is the first small molecule that has neurogenesis-inducing activity in non-pluripotent myoblasts and cells derived from skeletal muscle (Non-Patent Document 6). Neurodazine is an important bioactive molecule for generating nerve cells, but here too, molecules that can cause this bioactivity only at the desired time and place are desired as drugs in treatment and molecular tools in molecular biology research.

[0004] In order to meet the general demand for more selective expression of the physiological activity of low molecular weight compounds, a field of study on compounds that exhibit physiological activity only when irradiated with light, namely photophamacology, is currently gaining popularity (Non-Patent Document 7). In this field, compounds have been synthesized in which a photoreactive protecting group that can be removed by the action of light or a group whose molecular structure undergoes an isomerization reaction when exposed to light has been introduced as a photoswitch site for controlling physiological activity into a part of the molecular skeleton of a conventionally known protein inhibitor. [Prior art documents] [Non-patent literature]

[0005] [Non-Patent Document 1] Inman, GJ, et al., “SB-431542 is a potent and specific inhibitor of transforming growth factor-β superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7,” Molecular Pharmacology, 2002, Vol. 62, No. 1, p. 65-74 [Non-Patent Document 2] Hjelmeland, MD, et al., “SB-431542, a small molecule transforming growth factor-B-receptor antagonist, inhibits human glioma cell line proliferation and motility”, Molecular Cancer Therapeutics, 2004, Vol. 3, No. 6, p. 737-745 [Non-Patent Document 3] Davies, MR, et al., “TGF-β Small Molecule Inhibitor SB431542 Reduces Rotator Cuff Muscle Fibrosis and Fatty Infiltration By Promoting Fibro / Adipogenic Progenitor Apoptosis”, PLoS ONE, May 17, 2016, Vol. 11, No. 5, e0155486 [Non-Patent Document 4] Mezger, MC, et al., “Inhibitors of Activin Receptor-like Kinase 5 Interfere with SARS-CoV-2 S-Protein Processing and Spike-Mediated Cell Fusion via Attenuation of Furin Expression”, Viruses, June 15, 2022, Vol. 14, No. 6, 1308 [Non-Patent Document 5] Laping, NJ, et al., “Inhibition of transforming growth factor (TGF)-beta1-induced extracellular matrix with a novel inhibitor of the TGF-beta type I receptor kinase activity: SB-431542”, Molecular Pharmacology, 2002, Vol. 62, No. 1, p. 58-64. [Non-Patent Document 6] Williams, DR, et al., “Synthetic Small Molecules that Induce Neurogenesis in Skeletal Muscle”, J. Am. Chem. Soc., 2007, Vol. 129, No. 30, p. 9258-9259 [Non-Patent Document 7] Hull, K., et al., “In Vivo Photopharmacology”, Chemical Reviews, July 9, 2018, Vol. 118, No. 21, pp. 10710-10747 Summary of the Invention [Problem to be solved by the invention]

[0006] However, the former method had the problem that the detached molecular site was generated as a by-product when the protecting group was removed by light, and the latter method had the disadvantage that the biological activity was weaker than that of the original inhibitor because the site where the photoisomerization reaction occurs was different from the structure of the original inhibitor. The most promising approach is to generate inhibitors with optimized structures without producing by-products by using clean stimuli such as light or the reducing environment naturally present in tumor lesions.

[0007] An object of the present invention is to provide a precursor of an imidazole-based physiologically active substance that generates an imidazole-based physiologically active substance in response to an external stimulus or the environment, and a method for generating an imidazole-based physiologically active substance. [Means for solving the problem]

[0008] As a result of intensive research aimed at solving the above problems, the inventors have discovered that a precursor of an imidazole physiologically active substance having a 2H-imidazole-2-amine skeleton in its molecular structure produces an imidazole physiologically active substance in response to an external stimulus or the environment, and have thus completed the present invention.

[0009] The present invention includes the following aspects.

[0010] [1] A precursor of imidazole-based biologically active substances that has a 2H-imidazole-2-amine skeleton in its molecular structure and generates imidazole-based biologically active substances in response to external stimuli or the environment. [2] The precursor of an imidazole physiologically active substance according to [1], wherein the imidazole physiologically active substance is SB-431542. [3] The precursor of an imidazole physiologically active substance according to [1], wherein the imidazole physiologically active substance is SB-203580. [4] The precursor of an imidazole physiologically active substance described in [1], wherein the imidazole physiologically active substance is neurodazine. [5] A precursor of the imidazole physiologically active substance according to [2], which is a compound represented by any one selected from the group consisting of the following formulas (1) to (3): [ka] [6] A precursor of the imidazole physiologically active substance according to [3], which is a compound represented by the following formula (4): [ka] [7] A precursor of the imidazole physiologically active substance according to [4], which is a compound represented by the following formula (7): [ka] [8] The precursor of an imidazole-based physiologically active substance according to any one of [1] to [4], wherein the external stimulus or environment is light irradiation. [9] The precursor of an imidazole physiologically active substance according to any one of [1] to [4], wherein the external stimulus or environment is radiation exposure.

[10] The precursor of an imidazole physiologically active substance according to any one of [1] to [4], wherein the external stimulus or environment is a reducing environment.

[11] A method for producing an imidazole-based physiologically active substance, comprising irradiating a precursor of the imidazole-based physiologically active substance described in [8] with light.

[12] A method for producing an imidazole-based physiologically active substance, comprising irradiating a precursor of the imidazole-based physiologically active substance described in [9] with radiation.

[13] A method for producing an imidazole-based biologically active substance, comprising placing a precursor of the imidazole-based biologically active substance described in

[10] in a reducing environment.

[14] A method for producing an imidazole physiologically active substance, comprising placing a precursor of the imidazole physiologically active substance according to any one of [1] to [7] in a reducing environment and irradiating the precursor with light or radiation. Effect of the Invention

[0011] According to the present invention, it is possible to provide a precursor of an imidazole physiologically active substance that generates an imidazole physiologically active substance in response to an external stimulus or the environment, and a method for generating an imidazole physiologically active substance. [Brief description of the drawings]

[0012] [Figure 1] 1 shows chromatograms of the biimidazole-type SB-431542 precursor of Example 1 before and after irradiation with 360 nm light. Top: before irradiation, bottom: after irradiation. [Diagram 2] 2 shows chromatograms of the biimidazole-type SB-431542 precursor of Example 1 before and after irradiation with 405 nm light. Top: before irradiation, bottom: after irradiation. [Diagram 3]3 shows proton nuclear magnetic resonance spectra of dimethylamino-ASB of Example 2 before and after irradiation with 405 nm light. Top: before irradiation, middle: after irradiation, bottom: SB-431542. [Figure 4] 4 shows proton nuclear magnetic resonance spectra of sarcosine-ASB in Example 3 before and after irradiation with 405 nm light. Top: SB-431542, middle: after irradiation, bottom: before irradiation. [Diagram 5] 5 shows proton nuclear magnetic resonance images of dimethylaminoneurodazine before and after irradiation with 405 nm light in Example 4. Top: neurodazine, top middle: neurodazine precursor + neurodazine after irradiation with light, bottom middle: neurodazine precursor + neurodazine before irradiation with light, bottom: neurodazine precursor. [Figure 6] 6 shows proton nuclear magnetic resonance spectra of dimethylamino-2,4,5-triphenylimidazole in Example 5 before and after irradiation with 405 nm light. Top: before irradiation, middle: after irradiation, bottom: 2,4,5-triphenylimidazole. [Figure 7] FIG. 7 shows ultraviolet-visible absorption spectra of dimethylamino-2,4,5-triphenylimidazole in Example 5 at different irradiation times when irradiated with 405 nm light. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0013] Hereinafter, an embodiment of the present invention will be described in detail. However, the present invention is not limited to the embodiment described below, and various modifications are possible without departing from the gist of the present invention.

[0014] Electrospray ionization-Mass Spectroscopy (ESI-MS) is a mass spectrometry technique that uses electrospray ionization (ESI). ESI is one of the sample ionization methods in mass spectrometry, and can ionize macromolecules without fragmenting them. Proton nuclear magnetic resonance: 1H-NMR) is a type of nuclear magnetic resonance spectroscopy that detects hydrogen 1( 1 This is a technique for determining the structure of a molecule by measuring the nuclear magnetic resonance produced by the nuclei of hydrogen (H). Ultraviolet-visible absorption spectrum is a spectroscopic method that measures the absorption of light in the ultraviolet and visible regions. In this specification and claims, when a numerical range is expressed using "to", the numerical range includes the numerical values ​​on both sides of "to".

[0015] SB-431542 inhibits the phosphorylation enzymes of the TGF-β family, which are involved in signal transduction related to cell proliferation and cell movement. Although it has not yet been put to clinical use due to side effects and low solubility in water, it is an essential molecule for research into the TGF-β family signal transduction system. In recent years, it has also attracted attention as an essential component for inducing differentiation of iPS cells into nerve cells. SB-203580 inhibits the p38MAPK family of phosphorylating enzymes, which play a role in signal transduction related to inflammation and cell death, and is being investigated as a drug for the treatment of rheumatoid arthritis, inflammatory lung diseases, and cancer. Neurodazine is a small molecule that has neurogenesis-inducing activity in non-pluripotent myoblasts and cells derived from skeletal muscle, and is being investigated as a drug for degenerative brain diseases such as stroke, Parkinson's disease, and Alzheimer's disease. 2,4,5-Triphenylimidazole exhibits anti-inflammatory activity and is being investigated as an anti-inflammatory drug. In both cases, the challenge is how to suppress the inhibitory effects on normal cells.

[0016] [Precursors of imidazole-based biologically active substances] The precursor of the imidazole physiologically active substance of this embodiment (hereinafter also simply referred to as "precursor") has a 2H-imidazole-2-amine skeleton in its molecular structure and is characterized by generating an imidazole physiologically active substance in response to an external stimulus or environment.

[0017] In this embodiment, when the imidazole-based physiologically active substance is a compound represented by the following formula (A), the precursor of this embodiment is a compound represented by the following formula (B). [ka]

[0018] In formula (B), R1 and R2 each independently represent an organic group, a hydrogen atom, or a halogen atom, and when R1 and R2 are an organic group, they may be bonded to form a ring. In formulae (A) and (B), R3, R4, and R5 each independently represent an organic group, and may be bonded to form a ring.

[0019] When R1 and / or R2 is a halogen atom, it is preferably any one selected from the group consisting of a fluorine atom, a chlorine atom, and a bromine atom, and more preferably a chlorine atom. In the organic group, at least one hydrogen atom may be substituted with a halogen atom. In this case, the halogen atom is preferably any one selected from the group consisting of a fluorine atom, a chlorine atom, and a bromine atom, and more preferably a fluorine atom.

[0020] In formula (B), R1 and R2 are preferably each independently a hydrogen atom or an organic group, and -NR1R2 is more preferably a group consisting of a portion obtained by removing -NR1R2 from the compound of formula (B). In this case, the compound of formula (B) becomes a dimer of the compound of formula (A), and 2 moles of the compound of formula (A) can be produced from 1 mole of the compound of formula (B), and no by-products are produced, which is particularly preferred.

[0021] Specifically, the compound of formula (A) is preferably SB-431542 represented by the following formula (5), SB-203580 represented by the following formula (6), Neurodazine represented by the following formula (9), or 2,4,5-triphenylimidazole represented by the following formula (10), and more preferably SB-431542 represented by the following formula (5) or Neurodazine represented by the following formula (9).

[0022] [ka]

[0023] Specifically, the compound of formula (B) is preferably an SB-431542 precursor represented by any one selected from the group consisting of the following formulas (1) to (3), an SB-203580 precursor represented by the following formula (4), a neurodazine precursor represented by the following formula (7), or a 2,4,5-triphenylimidazole precursor represented by the following formula (8), more preferably an SB-431542 precursor represented by the following formula (1) or (2) or a neurodazine precursor represented by formula (7), and even more preferably an SB-431542 precursor represented by the following formula (2).

[0024] [ka]

[0025] The external stimulus may be, for example, light exposure and / or radiation exposure.

[0026] The light irradiation is not particularly limited as long as it is infrared light, visible light, ultraviolet light, or the like. The wavelength of light in the case of light irradiation is not particularly limited, but can be appropriately selected from 10 to 200 nm (far ultraviolet), 200 to 380 nm (near ultraviolet), 380 to 780 nm (visible light), 0.7 to 1.5 μm (near infrared), 2.5 to 4 μm (mid infrared), and 4 to 1000 μm (far infrared), and is preferably visible light of 400 to 410 nm. The photon flux density of the light is not particularly limited, but is preferably 1 to 20,000,000 μmol m -2 ·s -1 is preferably 10 to 10,000 μmol m -2 ·s -1 It is more preferable that: The integrated light quantity is not particularly limited, but is preferably 0.01 to 100,000 mJ, and more preferably 1 to 1,000 mJ.

[0027] The radiation irradiation is not particularly limited as long as it is particle radiation such as α-rays, β-rays, neutron rays, proton rays, or heavy ion rays, or electromagnetic radiation such as γ-rays or X-rays.

[0028] The environment may be, for example, a reducing environment. The reducing environment is, for example, an environment in which the redox potential is 2.8 V or less.

[0029] <Method of producing physiologically active substances> SB-431542 can be synthesized, for example, by the method of Callahan et al. (2002). That is, 4-fluorobenzoyl chloride and methoxy(methyl)amine are condensed to obtain N-methoxy-N-methyl-4-fluorobenzoic acid amide, which is then reacted with 2-methylpyridine lithiated with LDA to obtain 1-(4-fluorophenyl)-2-(2-pyridinyl)-ethanone. The obtained 1-(4-fluorophenyl)-2-(2-pyridinyl)-ethanone is treated with sodium nitrite under hydrochloric acid acid to obtain 1-(4-fluorophenyl)-2-imino-2-(2-pyridinyl)ethan-1-one, which is then condensed with 4-formylbenzonitrile to obtain an imidazole derivative. The cyano group of the resulting imidazole derivative is converted to a carboxylic acid by treatment with triethyl phosphite and then concentrated hydrochloric acid, after which it is derivatized into an acid chloride with oxalyl chloride, and finally reacted with aqueous ammonia to give SB-431542 as an acid amide. (References) Callahan et al., J. Med. Chem., 2002, 28;45(5), p.999-1001

[0030] SB-203580 can be obtained, for example, by heating 2-(tert-butyldimethylsilyloxy)-1-(4-fluorophenyl)-2-(4-pyridyl)ethanone and 4-(methylthio)benzaldehyde in acetic acid in the presence of ammonium acetate and copper acetate, followed by treatment with ammonium hydroxide to obtain the corresponding imidazole derivative, and then oxidizing the methylthio moiety with K2S2O8 in a mixed solvent of acetic acid and water.

[0031] Neurodazine can be obtained, for example, by suspending 5-(3-chlorophenyl)furfural, ammonium acetate, and 4,4'-dimethoxybenzyl in acetic acid, then heating to 100°C and stirring for 6 hours. The reaction mixture is then diluted with ethyl acetate, washed with saturated NaHCO3 and brine, the organic layer is concentrated under reduced pressure, and the resulting mixture is purified by flash column chromatography.

[0032] 2,4,5-Triphenylimidazole can be obtained, for example, by stirring benzyl, ammonium acetate, acetic anhydride, and benzaldehyde at 100°C for 4 hours, adding water and then ammonium hydroxide to neutralize the acid, filtering the precipitate formed by continuous stirring, washing the solid with toluene, and recrystallizing it from methanol.

[0033] <Precursor manufacturing method> The compound of formula (1) can be produced by oxidation of SB-431542. The oxidation method can be the synthesis method of hexaphenylbiimidazole by oxidation of other 2,4,5-triphenylimidazole (Hayashi et al., 1960; White et al., 1966; Coraor et al., 1971) or a modified method for SB-431542. (References) Hayashi et al., Bull. Chem. Soc. Jpn., 1960, Vol. 33, p. 565 White et al., J. Am. Chem. Soc., 1966, Vol. 88, No. 16, pp. 3825-3829 Coraor et al., J. Org. Chem., 1971, Vol. 36, No. 16, pp. 2262-2267

[0034] More specifically, SB-431542 dissolved in an organic solvent can be oxidized in a two-phase system with potassium hydroxide and potassium ferricyanide dissolved in water to obtain a SB-431542 precursor containing a 2H-imidazole-2-amine skeleton. In this case, the amine moiety at the 2-position can be made into a structure different from that of imidazole by adding an amine. Various oxidizing agents can be used, such as the method using lead dioxide as an oxidizing agent described in White et al. (1966). In addition, as for the reaction solvent, combinations of benzene / water, ethyl acetate / water, ethanol, and other organic solvents, and one-phase systems can be used. However, it is desirable to select a solvent that contains at least one solvent (e.g., ethyl acetate) that shows a certain degree of solubility for SB-431542. Various environments can be used for the reaction atmosphere, such as a nitrogen atmosphere, air, and argon atmosphere. As for the reaction temperature, the reaction can be carried out at various temperatures from about 10°C to the boiling point of the solvent.

[0035] The compound of formula (2) can be obtained, for example, by dissolving SB-431542 in DMF (dimethylformamide), adding an aqueous solution of potassium hydroxide, potassium ferricyanide (K3[Fe(CN)6]), and dimethylamine, vigorously stirring under a nitrogen atmosphere, adding water, extracting with ethyl acetate, removing the ethyl acetate under reduced pressure, separating the product using a preparative reverse-phase gradient HPLC, and removing the solvent under reduced pressure.

[0036] The compound of formula (3) can be obtained, for example, by dissolving SB-431542 in DMF (dimethylformamide), adding an aqueous solution of potassium hydroxide, potassium ferricyanide (K3[Fe(CN)6]), and N-methylglycine, vigorously stirring under a nitrogen atmosphere, adding water, extracting with ethyl acetate, removing the ethyl acetate under reduced pressure, separating the product using a preparative reverse-phase gradient HPLC, and removing the solvent under reduced pressure.

[0037] The compound of formula (7) can be obtained, for example, by dissolving neurodazine in DMF (dimethylformamide), adding an aqueous solution of potassium hydroxide, potassium ferricyanide (K3[Fe(CN)6]), and dimethylamine, vigorously stirring under a nitrogen atmosphere, adding water, extracting with ethyl acetate, removing the ethyl acetate under reduced pressure, separating the product using a preparative reverse-phase gradient HPLC, and removing the solvent under reduced pressure.

[0038] The compound of formula (8) can be obtained, for example, by dissolving 2,4,5-triphenylimidazole in DMF (dimethylformamide), adding an aqueous solution of potassium hydroxide, potassium ferricyanide (K3[Fe(CN)6]), and dimethylamine, vigorously stirring under a nitrogen atmosphere, adding water, extracting with ethyl acetate, removing the ethyl acetate under reduced pressure, separating the product using a preparative reverse-phase gradient HPLC, and removing the solvent under reduced pressure.

[0039] [Method for producing imidazole-based physiologically active substances] The method for producing an imidazole-based physiologically active substance of this embodiment (hereinafter also simply referred to as the "production method") includes placing a precursor of the imidazole-based physiologically active substance described above in a reducing environment and / or irradiating it with light or radiation. In the case where both placing in a reducing environment and irradiating with light or radiation are included, the light irradiation or radiation irradiation may be performed while placing in the reducing environment, or the placing in the reducing environment and the light irradiation or radiation irradiation may be separated in time.

[0040] The production method of this embodiment may be performed in vitro or in vivo.

[0041] The light irradiation is not particularly limited as long as it is infrared light, visible light, ultraviolet light, or the like. The wavelength of light in the case of light irradiation is not particularly limited, but can be appropriately selected from 10 to 200 nm (far ultraviolet), 200 to 380 nm (near ultraviolet), 380 to 780 nm (visible light), 0.7 to 1.5 μm (near infrared), 2.5 to 4 μm (mid infrared), and 4 to 1000 μm (far infrared), and is preferably visible light of 400 to 410 nm. The photon flux density of the light is not particularly limited, but is preferably 1 to 20,000,000 μmol m -2 ·s -1 is preferably 10 to 10,000 μmol m -2 ·s -1 It is more preferable that: The integrated light quantity is not particularly limited, but is preferably 0.01 to 100,000 mJ, and more preferably 1 to 1,000 mJ.

[0042] The radiation irradiation is not particularly limited as long as it is particle radiation such as α-rays, β-rays, neutron rays, proton rays, or heavy ion rays, or electromagnetic radiation such as γ-rays or X-rays.

[0043] The environment may be, for example, a reducing environment. The reducing environment is, for example, an environment in which the redox potential is 2.8 V or less. A method for providing a reducing environment includes adding a reducing agent to the medium, and various reducing agents such as glutathione, dithiothreitol, and lithium aluminum hydride can be used as the reducing agent. Furthermore, imidazole-based bioactive substances can be produced from precursors of biimidazole-based imidazole-based bioactive substances without the presence of a special reducing agent. This is because the oxidizing power of intermediates produced from the precursors of biimidazole-based imidazole-based bioactive substances is high enough to abstract hydrogen from the surrounding solvents, proteins, and other biological substances (which act as reducing agents). In particular, when obtaining imidazole-based bioactive substances from precursors of biimidazole-based imidazole-based bioactive substances in cells, reducing compounds already present in the cells provide hydrogen, so there is no need to actively add a reducing agent.

[0044] The precursor of a biimidazole-type imidazole bioactive substance can be dissolved in an organic solvent or an aqueous solvent, and then added to a target system and exposed to light irradiation, radiation irradiation, a reducing environment, or a combination of these stimuli to produce an imidazole bioactive substance without producing any by-products, except for the production of an oxide of the reducing compound (for example, oxidized glutathione when the reducing compound is reduced glutathione present in the body).

[0045] According to the present invention, by focusing light or radiation on a desired location and irradiating the location at a desired timing, it is possible to selectively generate an imidazole-based physiologically active substance and exert its physiological activity. Furthermore, if there is a location that exhibits high reducing activity, it is possible to more efficiently generate an imidazole-based physiologically active substance only at that location and exert its physiological activity. EXAMPLES

[0046] The present invention will be described in more detail below with reference to examples, although the present invention is not limited to the examples described below.

[0047] [Example 1] 1. Synthesis of biimidazole-type SB-431542 precursor [compound of formula (1)] 100 mg of SB-431542 [compound of formula (5)] was dissolved in 50 mL of ethyl acetate, and an aqueous solution of potassium hydroxide and potassium ferricyanide was added and vigorously stirred at 30 °C under a nitrogen atmosphere to carry out an oxidation reaction. The obtained organic layer was concentrated and purified by reverse phase liquid chromatography (acetonitrile / water, gradient) to obtain the biimidazole fraction. The solvent was removed to obtain 10 mg of biimidazole-type SB-431542 precursor [compound of formula (1)] as a pale yellow powder. Electrospray ionization mass spectrometry gave a molecular weight of 766 (observed as a peak of M + H = 767) (the molecular weight of SB-431542 is 384), and the biimidazole structure in which two hydrogen atoms were removed from SB-431542 and bonded was confirmed.

[0048] 2. Evaluation of biimidazole-type SB-431542 precursors Biimidazole-type SB-431542 precursor was dissolved at a concentration of 0.1 mM in a mixed solvent of water:acetonitrile = 3:1 containing 1 mM glutathione, and irradiated with an LED light source emitting 360 nm or 405 nm light for a certain period of time. When the solution was analyzed by reverse phase liquid chromatography (acetonitrile / water, gradient), the peak intensity of the SB-431542 precursor decreased with increasing irradiation time, while the peak intensity of SB-431542 increased at the same time (Figures 1 and 2). Only two peaks appeared in the chromatogram, indicating that only the conversion from SB-431542 precursor to SB-431542 occurred due to light.

[0049] [ka]

[0050] [Example 2] 1. Synthesis of dimethylamino-ASB [compound of formula (2)] 100 mg of SB-431542 [compound of formula (5)] was dissolved in 50 mL of dimethylformamide containing dimethylamine, and an aqueous solution of potassium hydroxide and potassium ferricyanide was added and vigorously stirred at 30 °C under a nitrogen atmosphere to carry out an oxidation reaction. After concentration, the mixture was purified by reverse phase liquid chromatography (acetonitrile / water, gradient) to obtain the fraction of 2H-imidazole-2-amine. The solvent was removed to obtain 17 mg of SB-431542 precursor [compound of formula (2)] containing a 2H-imidazole-2-amine skeleton as a pale yellow powder. Electrospray ionization mass spectrometry gave a molecular weight of 427 (observed as a peak at M+Na=450) (the molecular weight of SB-431542 is 384), and the structure containing a 2H-imidazole-2-amine structure in which a dimethylamino group is substituted for the carbon at the 2nd position of the imidazole in SB-431542 was confirmed.

[0051] [ka]

[0052] 2. Evaluation of Dimethylamino-ASB Dimethylamino-ASB was dissolved in a 1:1 volumetric mixture of deuterium oxide and deuterated acetonitrile. 1 H-NMR was measured, and then the sample was irradiated with light from a 405 nm LED light source for 10 minutes. 1 H-NMR was measured to confirm the identity of SB-431542 and dimethylamino-ASB. 1 The H-NMR peak positions were compared, and the peak of dimethylamino-ASB disappeared, and a new peak of SB-431542 appeared (Figure 3).

[0053] [Example 3] 1. Synthesis of Sarcosine-ASB [Compound of formula (3)] SB-431542 [compound of formula (5)] (100 mg, 0.078 mmol) was dissolved in DMF (2 mL), and 8.0 mL of an aqueous solution containing 7.0 g of KOH, 14.0 g of K3[Fe(CN)6], and 880 mg of N-methylglycine was added, and the mixture was stirred vigorously at 30°C for 24 hours under a nitrogen atmosphere. Then, 10 mL of water was added, and the mixture was extracted three times with ethyl acetate. The ethyl acetate was removed under reduced pressure, and the mixture was separated by reversed-phase gradient HPLC for separation (acetonitrile concentration in water 30%-70%, 4 hours, flow rate 10 mL / min). The solvent was removed under reduced pressure, and 2 mg of pale yellow sarcosine-ASB [compound of formula (3)] was obtained. The molecular structure is 1 The results were confirmed by H-NMR and ESI-MS.

[0054] [ka]

[0055] 2. Evaluation of Sarcosine-ASB Sarcosine-ASB was dissolved in a 1:1 volumetric mixture of deuterium oxide and deuterated acetonitrile. 1 H-NMR was measured, and then the sample was irradiated with light from a 405 nm LED light source for 10 minutes. 1 H-NMR was measured to confirm the identity of SB-431542 and sarcosine-ASB. 1The H-NMR peak positions were compared, and the result showed that the sarcosine-ASB peak disappeared and a new SB-431542 peak appeared (Figure 4).

[0056] [Example 4] 1. Synthesis of dimethylaminoneurodazine [compound of formula (7)] Neurodazine (compound of formula (9)) (20.0 mg, 0.044 mmol) and 1 mL of dimethylamine (approximately 7% in N,N-dimethylformamide (DMF)) were mixed, and 1 mL of an aqueous solution containing KOH (0.07 g, 0.13 mmol) and K3[Fe(CN)6] (0.14 g, 0.44 mmol) was added to the solution. The reaction mixture was vigorously stirred at 45 °C for 24 h. After the reaction, 10 mL of water was added to the reaction mixture, and it was extracted with ethyl acetate (20 mL × 3). The organic extract was dried over anhydrous MgSO4, the solvent was evaporated, and then it was purified by gradient high performance liquid chromatography (HPLC) using 60-80% acetonitrile / water as a solvent. After purification, it was lyophilized to obtain the neurodazine precursor (compound of formula (7)) as a pale yellow powder (2.7 mg, yield = 12%).

[0057] [ka]

[0058] 2. Evaluation of Dimethylaminoneurodazine A 2:3 molar mixture of dimethylaminoneurodazine and neurodazine (neurodazine was used as an internal standard compound) was dissolved in a 1:1 volumetric mixture of deuterium oxide and deuterated acetonitrile. 1 H-NMR was measured, and then the sample was irradiated with light from a 405 nm LED light source for 20 minutes. 1 H-NMR was measured to confirm the identity of Neurodazine and dimethylaminoneurodazine. 1 The H-NMR peak positions were compared, and the result showed that the dimethylaminoneurodazine peak disappeared, and only the neurodazine peak remained (Figure 5).

[0059] [Example 5] 1. Synthesis of dimethylamino-2,4,5-triphenylimidazole [compound of formula (8)] 2,4,5-Triphenylimidazole [compound of formula (10)] (1 g, 3.37 mmol) and dimethylamine (approximately 7% in N,N-dimethylformamide (DMF), 22 mL) were mixed, and 337.4 mL of an aqueous solution containing KOH (24.6 g, 43.5 mmol) and K3[Fe(CN)6] (48.87 g, 146.6 mmol) was added to the solution. The reaction mixture was vigorously stirred at room temperature under nitrogen atmosphere for 24 hours. After the reaction, 10 mL of water was added and extracted with ethyl acetate (20 mL x 3). The organic extract was dried over anhydrous MgSO4, and the solvent was removed under reduced pressure. The product was purified by silica gel column chromatography using dichloromethane containing 2% methanol. 2,4,5-Triphenylimidazole precursor [compound of formula (8)] was obtained as a pale yellow powder (0.28 g, yield = 24%).

[0060] [ka]

[0061] 2. Evaluation of dimethylamino-2,4,5-triphenylimidazole Dimethylamino-2,4,5-triphenylimidazole was dissolved in a 1:1 volumetric mixture of deuterium oxide and deuterated acetonitrile. 1 H-NMR was measured, and then the sample was irradiated with light from a 405 nm LED light source for 10 minutes. 1 H-NMR was measured to confirm the identity of 2,4,5-triphenylimidazole and dimethylamino-2,4,5-triphenylimidazole. 1 The H-NMR peak positions were compared, and the result was that the dimethylamino-2,4,5-triphenylimidazole peak disappeared, and a new 2,4,5-triphenylimidazole peak appeared (Figure 6).

[0062] 4.5 × 10 2,4,5-triphenylimidazole precursor was added to a 9:1 volumetric mixture of acetonitrile and water. -5When it was dissolved at a concentration of 1 mol / L and irradiated for a certain period of time with an LED light source emitting 405 nm light, and the solution was analyzed with a UV-visible spectrophotometer (Asahi Spectroscopy, CL-H1-405-9-1-B), it was found that the UV-visible absorption spectrum changed with increasing irradiation time, indicating that the 2,4,5-triphenylimidazole precursor was changing to 2,4,5-triphenylimidazole (Figure 7). [Industrial Applicability]

[0063] In the present invention, by focusing light or radiation on a desired location and irradiating the location at a desired timing, it is possible to selectively generate an imidazole-based physiologically active substance and exert its physiological activity. Furthermore, if there is a location that exhibits high reducing activity, it is possible to more efficiently generate an imidazole-based physiologically active substance only at that location and exert its physiological activity.

[0064] Therefore, the inhibitory effect on normal cells can be suppressed, and a safer imidazole-based physiologically active substance can be provided.

Claims

1. A precursor of an imidazole-based physiologically active substance, which has a 2H-imidazole-2-amine skeleton in its molecular structure and generates an imidazole-based physiologically active substance in response to an external stimulus or environment.

2. 2. The precursor of an imidazole-based physiologically active substance according to claim 1, wherein the imidazole-based physiologically active substance is SB-431542.

3. 2. The precursor of an imidazole-based physiologically active substance according to claim 1, wherein the imidazole-based physiologically active substance is SB-203580.

4. The precursor of an imidazole bioactive substance according to claim 1 , wherein the imidazole bioactive substance is neurodazine.

5. 3. The precursor of an imidazole-based physiologically active substance according to claim 2, which is a compound represented by any one selected from the group consisting of the following formulas (1) to (3): [Formula 1]

6. 4. A precursor of the imidazole physiologically active substance according to claim 3, which is a compound represented by the following formula (4): [chemical 2]

7. 5. The precursor of the imidazole physiologically active substance according to claim 4, which is a compound represented by the following formula (7): [C3]

8. The precursor of an imidazole-based physiologically active substance according to any one of claims 1 to 4, wherein the external stimulus or environment is light irradiation.

9. The precursor of an imidazole-based physiologically active substance according to any one of claims 1 to 4, wherein the external stimulus or environment is radiation exposure.

10. The precursor of an imidazole-based physiologically active substance according to any one of claims 1 to 4, wherein the external stimulus or environment is a reducing environment.

11. A method for producing an imidazole-based physiologically active substance, comprising irradiating a precursor of the imidazole-based physiologically active substance according to claim 8 with light.

12. A method for producing an imidazole-based physiologically active substance, comprising irradiating a precursor of the imidazole-based physiologically active substance according to claim 9 with radiation.

13. A method for producing an imidazole-based biologically active substance, comprising placing a precursor of the imidazole-based biologically active substance according to claim 10 in a reducing environment.

14. A method for producing an imidazole-based physiologically active substance, comprising placing a precursor of the imidazole-based physiologically active substance according to any one of claims 1 to 7 in a reducing environment and irradiating the precursor with light or radiation.